Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Kim SS, Chung JR, Belongia EA, McLean HQ, King JP, Nowalk MP, Zimmerman RK, Balasubramani GK, Martin ET, Monto AS, Lamerato LE, Gaglani M, Smith ME, Dunnigan KM, Jackson ML, Jackson LA, Tenforde MW, Verani JR, Kobayashi M, Schrag S, Patel MM, Flannery B. mRNA vaccine effectiveness against COVID-19 among symptomatic outpatients aged =16 years in the United States,February - May 2021. J Infect Dis. 2021 Sep 8:jiab451. doi: 10.1093/infdis/jiab451. Online ahead of print. PubMed
Griggs EP, Flannery B, Foppa IM, Gaglani M, Murthy K, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Martin ET, Monto AS, Zimmerman RK, Balasubramani GK, Chung JR, Patel M, Us Flu Ve Investigators OBOT. Role of Age in Spread of Influenza, 2011-2019, U.S. Influenza Vaccine Effectiveness Network. LID - kwab205 [pii] LID - 10.1093/aje/kwab205 [doi] Am J Epidemiol. 2021 Jul 16:kwab205. doi: 10.1093/aje/kwab205 [Epub ahead of print] PubMed
Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, Clark A, de Villiers MJ, Eilertson K, Ferrari M, Gamkrelidze I, Hallett TB, Hinsley WR, Hogan D, Huber JH, Jackson ML, Jean K, Jit M, Karachaliou A, Klepac P, Kraay A, Lessler J, Li X, Lopman BA, Mengistu T, Metcalf CJE, Moore SM, Nayagam S, Papadopoulos T, Perkins TA, Portnoy A, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Tam Y, Tanvir H, Tran Minh Q, Trotter CL, Truelove SA, Vynnycky E, Walker N, Winter A, Woodruff K, Ferguson NM, Gaythorpe KA. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. Elife. 2021 Jul 13;10:e67635. doi: 10.7554/eLife.67635. PubMed
Daley MF, Reifler LM, Shoup JA, Narwaney KJ, Kharbanda EO, Groom HC, Jackson ML, Jacobsen SJ, McLean HQ, Klein NP, Williams JTB, Weintraub ES, McNeil MM, Glanz JM. Temporal Trends in Undervaccination: A Population-Based Cohort Study. Am J Prev Med. 2021;61(1):64-72. doi: 10.1016/j.amepre.2021.01.037. Epub 2021 Apr 30. PubMed
Gaythorpe KA, Abbas K, Huber J, Karachaliou A, Thakkar N, Woodruff K, Li X, Echeverria-Londono S, Ferrari M, Jackson ML, McCarthy K, Perkins TA, Trotter C, Jit M. Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. Elife. 2021 Jun 24;10:e67023. doi: 10.7554/eLife.67023. Online ahead of print. PubMed
Chung JR, Flannery B, Kim SS, Gaglani M, Raiyani C, Belongia EA, McLean HQ, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Martin ET, Monto AS, Patel M. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021 May 13:S0264-410X(21)00555-7. doi: 10.1016/j.vaccine.2021.05.004. Online ahead of print. PubMed
Flannery B, Meece JK, Williams JV, Martin ET, Gaglani M, Jackson ML, Talbot HK, US Influenza Vaccine Effectiveness Network and the Hospitalized Adult Influenza Vaccine Effectiveness Network. Systematic testing for influenza and coronavirus disease 2019 among patients with respiratory illness. Clin Infect Dis. 2021 May 4;72(9):e426-e428. doi: 10.1093/cid/ciaa1023. PubMed
Heimonen J, McCulloch DJ, O'Hanlon J, Kim AE, Emanuels A, Wilcox N, Brandstetter E, Stewart M, McCune D, Fry S, Parsons S, Hughes JP, Jackson ML, Uyeki TM, Boeckh M, Starita LM, Bedford T, Englund JA, Chu HY. A remote household-based approach to influenza self-testing and antiviral treatment. Influenza Other Respir Viruses. 2021 May 3. doi: 10.1111/irv.12859. [Epub ahead of print]. PubMed
Jackson ML, Hart GR, McCulloch DJ, Adler A, Brandstetter E, Fay K, Han P, Lacombe K, Lee J, Sibley TR, Nickerson DA, Rieder MJ, Starita L, Englund JA, Bedford T, Chu H, Famulare M. Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study. BMC Infect Dis. 2021;21(1):335. doi: 10.1186/s12879-021-06028-4. PubMed
Jackson ML, Ferdinands J, Nowalk MP, Zimmerman RK, Kieke B, Gaglani M, Murthy K, Petrie JG, Martin ET, Chung JR, Flannery B, Jackson LA. Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study. BMC Public Health. 2021;21(1):516. doi: 10.1186/s12889-021-10543-z. PubMed
Vaccines given in last 20 years could prevent 50 million deaths in 112 countries
Answers to 4 questions about COVID-19 and this season's flu, from KPWHRI's Michael Jackson, PhD, MPH.
In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Verywell Health, Jan. 13, 2021
KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.
WebMD, Sept. 2, 2020